~~<i id='E92B0164EB'><strike id='E92B0164EB'><tt id='E92B0164EB'><pre id='E92B0164EB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：focus 2025-10-02 00:41:46 - browse：54643

glum Benjamin — health insurance coverage from STAT — Adobe

Startup insurers Oscar Health, Bright Health, and Clover Health have hemorrhaged money since going public within the past two years. All three used their stage time at the J.P. Morgan Healthcare Conference to make the case that their drastic decisions — like fully exiting some insurance markets — will deliver the profitability investors are demanding.

“Insurance company profitability is the number one goal,” Oscar CEO Mario Schlosser said in an interview with STAT in San Francisco.

“We are actually absolutely focused on profitability right now,” Clover CEO Andrew Toy said during his presentation on Wednesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： UnitedHealth quietly bought dozens of outpatient centers

leisure time

focus

hotspot

entertainment

focus

leisure time

AmandaAndrade-Rhoades/APU.S.regulatorsapprovedalabelexpansionforNovoNordisk’sobesitydrugWegovytotout

WSS

Christmas in the PICU brings some surprising joy

Hospitals owned by private equity see complications spike 25%

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

With psoriasis trial ahead, Alumis raises $259 million

The drug industry has found itself all alone in Washington

HCA sued by state AG for quality issues at Mission Health

knowledge

fashion

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Medicare Advantage beneficiaries sue Humana over algorithm use

Heart attack and stroke risk calculators need revising

RSV shot was 90% effective at preventing hospitalizations in kids

Virginia high school admissions case could be legal follow

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Duchenne breakthrough therapy leaves behind pioneering families

Can sheer will power keep patients alive in their dying hours?

Bright Health sells Medicare Advantage business to Molina

Prime Medicine, Myeloid Therapeutics clash over genome

focus

Editas, Vertex strike deal on CRISPR

How to bring more disabled researchers into academia

Amylyx ALS drug failure raises questions and concerns

IVF, abortion rights issues kick off Biden’s State of the Union

Editas, Vertex strike deal on CRISPR

A deep dive into Applied Therapeutics’ data, and questions on Cassava

hotspot

entertainment

focus

leisure time